Literature DB >> 8828606

Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria.

P Burgard1, E Schmidt, A Rupp, W Schneider, H J Bremer.   

Abstract

In a multicentric and interdisciplinary approach the German Collaborative Study of Children Treated for Phenylketonuria (PKU) investigates prospectively the effects of early started strict dietary treatment on the growth and development of 140 patients. The present paper focuses on longitudinal intelligence data from 4, 5 and 9 years of age of 89 patients in relation to the quality of dietary control in comparison to 200 healthy children tested by the same protocol. Cluster analysis of phenylalanine (Phe) levels distinguished a cluster of good dietary control with Phe levels according to the recommendation of maintaining Phe levels below 360 mumol/l, a cluster of poor dietary control with Phe levels greater than 600 mumol/l after the age of 3 years, and a cluster of intermediate control. Intelligence quotients (IQ) and Phe clusters were inversely related with non-significant differences between the clusters good and intermediate. On average, all three clusters scored significantly lower than healthy age peers. Mean IQ scores decreased for patients as well as for healthy children due to different tests used at different measurement occasions. Patients with poor dietary control showed a steeper decrease between 4 and 5 years than patients with better dietary control. Between 5 and 9 years IQ differences between patients and healthy children remained stable. Verbal IQs were higher than performance IQs for patients as well as for healthy children. It is concluded that after early and strict treatment during the pre-school years Phe levels, in the range observed, do not influence IQ development until the age of 9 years. IQ subscale pattern indicate that PKU results in a generalized reduction of IQ instead of disturbing specific abilities. It remains to be investigated whether higher Phe levels are also innocuous and/or may result in late effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8828606     DOI: 10.1007/pl00014245

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  23 in total

1.  Rising IQ scores in British children: recent evidence.

Authors:  P W Fuggle; S Tokar; D B Grant; I Smith
Journal:  J Child Psychol Psychiatry       Date:  1992-10       Impact factor: 8.982

Review 2.  Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome.

Authors:  S E Waisbren; R R Schnell; H L Levy
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

3.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Authors:  M C Welsh; B F Pennington; S Ozonoff; B Rouse; E R McCabe
Journal:  Child Dev       Date:  1990-12

4.  Nutrient intake and food consumption of adolescents and young adults with phenylketonuria.

Authors:  B Schulz; H J Bremer
Journal:  Acta Paediatr       Date:  1995-07       Impact factor: 2.299

5.  Intelligence and quality of dietary treatment in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

Review 6.  Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria.

Authors: 
Journal:  BMJ       Date:  1993-01-09

7.  Psychopathology of patients treated early for phenylketonuria: results of the German collaborative study of phenylketonuria.

Authors:  P Burgard; M Armbruster; E Schmidt; A Rupp
Journal:  Acta Paediatr Suppl       Date:  1994-12

8.  Collaborative study of children treated for phenylketonuria: study design.

Authors:  M Williamson; J C Dobson; R Koch
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

9.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

10.  Personality characteristics in patients with phenylketonuria treated early.

Authors:  J Weglage; A Rupp; E Schmidt
Journal:  Pediatr Res       Date:  1994-05       Impact factor: 3.756

View more
  19 in total

1.  Living situation, occupation and health-related quality of life in adult patients with classic galactosemia.

Authors:  Björn Hoffmann; Nico Dragano; Susanne Schweitzer-Krantz
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

2.  Brain phenylalanine concentration in the management of adults with phenylketonuria.

Authors:  R A Moats; R Koch; K Moseley; P Guldberg; F Guttler; R G Boles; M D Nelson
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

3.  Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia.

Authors:  L G Greeves; C C Patterson; D J Carson; R Thom; M C Wolfenden; J Zschocke; C A Graham; N C Nevin; E R Trimble
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

4.  Pyruvate and creatine prevent oxidative stress and behavioral alterations caused by phenylalanine administration into hippocampus of rats.

Authors:  Simone Luisa Berti; Guilherme Marmontel Nasi; Cristina Garcia; Fernanda Luz de Castro; Michely Lopes Nunes; Denise Bertin Rojas; Tarsila Barros Moraes; Carlos Severo Dutra-Filho; Clóvis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2011-11-19       Impact factor: 3.584

Review 5.  The reality of dietary compliance in the management of phenylketonuria.

Authors:  Anita MacDonald; Hulya Gokmen-Ozel; Margreet van Rijn; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

6.  Neurocognitive profiles in MSUD school-age patients.

Authors:  Juliette Bouchereau; Julie Leduc-Leballeur; Samia Pichard; Apolline Imbard; Jean-François Benoist; Marie-Thérèse Abi Warde; Jean-Baptiste Arnoux; Valérie Barbier; Anaïs Brassier; Pierre Broué; Aline Cano; Brigitte Chabrol; Gilles Damon; Claire Gay; Isabelle Guillain; Florence Habarou; Delphine Lamireau; Chris Ottolenghi; Laetitia Paermentier; Frédérique Sabourdy; Guy Touati; Hélène Ogier de Baulny; Pascale de Lonlay; Manuel Schiff
Journal:  J Inherit Metab Dis       Date:  2017-03-21       Impact factor: 4.982

7.  Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence.

Authors:  J Weglage; M Pietsch; J Denecke; A Sprinz; R Feldmann; M Grenzebach; K Ullrich
Journal:  J Inherit Metab Dis       Date:  1999-08       Impact factor: 4.982

Review 8.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

9.  Executive function impairment in early-treated PKU subjects with normal mental development.

Authors:  V Leuzzi; M Pansini; E Sechi; F Chiarotti; Cl Carducci; G Levi; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

10.  Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia.

Authors:  G Gramer; P Burgard; S F Garbade; M Lindner
Journal:  J Inherit Metab Dis       Date:  2007-08-06       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.